KZAP
22 años hace
PANA (OTCBB) PanaMed Corporation's HIV/AIDS Treatment Program Moves to Larger Facility
WEDNESDAY, OCTOBER 09, 2002 08:30 AM
INDIANAPOLIS, Oct 9, 2002 (BUSINESS WIRE) -- PanaMed Corporation (OTCBB:PANA) announces today that the company has acquired the use of a new and larger inpatient facility in Africa. The new facility will house the Company's HIV/AIDS Treatment Program. Additionally, the new facility has been secured under a stable lease agreement and is capable of accommodating all anticipated needs for the full course of the treatment program.
PanaMed also announces that the Company had relocated its Corporate Headquarters to Lebanon, Indiana. Lebanon is approximately 20 miles northwest of Indianapolis. The Company's newly acquired and highly secure headquarters are significantly larger than the Company's previous headquarters. This transition will allow for smooth and seamless growth as the company expands its operational structure. The address of PanaMed's new Corporate Headquarters is as follows:
PanaMed Corporation
127 West Main Street
Second Floor
Lebanon, Indiana 46052
This document contains forward-looking statements. There are certain important factors that could cause results to differ materially from those anticipated by the statements made above. Additional information on these and other factors will be included on future 10-Q and 10-K reports.
CONTACT: PanaMed Corporation
Phillip Butler, 800/388-0750 or 765/483-9670
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
Happy Investing!
KZAP
jmhollen
22 años hace
PanaMed Corporation Concludes Stage One of Treatment Program for HIV/AIDS Therapeutic. Stage Two to Include Larger Patient Base.
The first human treatment program with PanaMed's candidate HIV/AIDS therapeutic was designed to ascertain whether the therapeutic is safe and efficacious.
Wednesday September 25, 8:30 am ET
INDIANAPOLIS--(BUSINESS WIRE)--Sept. 25, 2002-- Indianapolis based PanaMed Corporation announces today that the Company concluded Stage One of the first human treatment program for its immunomodulating therapeutic to treat patients infected with the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). Currently, a majority of the patients who have received treatment since commencement of the Company's program in June appear to tolerate well the dosages being administered and to demonstrate positive reactions. As data is being further analyzed it is premature to project conclusive long-term results.
Due to the progress achieved in Stage One, the Company is preparing to expand into Stage Two of its human treatment program for the candidate therapeutic. While the main objectives of Stage Two are identical to those of Stage One, Stage Two of the program will include a larger group of patients.
The main objectives of both Stage One and Stage Two of the Company's program are to test, record and analyze patient response to different dosage levels of the therapeutic, which is being administered in a controlled, inpatient setting, in terms of tolerance and safety, whether and how dosages generate reactions by the patient's immune system, and whether and to what extent the therapeutic reduces the viral load within the patient's body.
General information on HIV and AIDS:
The human immunodeficiency virus (HIV) is a retrovirus. HIV is structurally simple, essentially consisting of genes and enzymes encased in a protein capsule. This design requires HIV to replicate inside host cells. HIV's favorite hosts are white blood cells called helper T cells in which the virus docks with molecules on those cells called CD4 and CCR5. Once HIV binds itself to a receptor on a host cell the virus begins uncoating inside the cell; during uncoating, the protein capsule breaks up, releasing the virus's genes. HIV then transcribes genes into mobile strands of messenger RNA, which the host cell translates, or uses as a guide for making the encoded proteins. The viral genome, which takes the form of DNA, is then freed for copying and directing the production of viral proteins. Once these freshly formed viral particles are produced they escape from the cell and migrate to, attack, and destroy new healthy host cells. In time and after continual replication and the corresponding destruction of helper T cells, the HI virus causes acquired immunodeficiency syndrome (AIDS). AIDS is the final and most serious stage of HIV disease, in which the signs and symptoms of severe immune deficiency have developed. The HI virus, in an AIDS patient, effectively floods the body's immune response disabling its ability to fight off foreign entities such as additional infections.
World Health Organization (WHO) reports estimate that HIV has infected more than 50 million people worldwide. Approximately 15,000 new patients are infected each day.
Contact:
PanaMed Corporation
Phillip Butler, 800/388-0750
Park your Sub at the iHub - Bub; .....the experience might just "...float your boat..." !!!
jmhollen
22 años hace
PANA (OTCBB) PanaMed Launches HIV Treatment Program
WEDNESDAY, JUNE 19, 2002 08:03 AM
CAMARILLO, Calif., Jun 19, 2002 (BUSINESS WIRE) -- PanaMed Corporation (OTCBB:PANA) announced today it has initiated a limited treatment program in a single West African nation using "Viro-Net," a therapeutic with potential for treating HIV/AIDS and related health conditions in third world countries. Viro-Net, supplied exclusively by Havel Investments Limited, has been in development for many years. Completion of this program is expected to be a major step in the future commercialization of the product.
Viro-Net is expected to demonstrate a high degree of effectiveness in the treatment of patients in a controlled and monitored environment. Local medical personnel will oversee the treatments which will be conducted in a government certified clinic and will use sophisticated equipment for monitoring patient progress. PanaMed expects that upwards of 60 patients will be treated during the first Phase of the program.
"We are extremely pleased with the enthusiastic reception received from the West African representatives supporting this project. I believe we are on the threshold of making a difference in this region of the world," stated Phil Butler, CEO of PanaMed. "These people are searching for an alternative to the conventional HIV/AIDS medications used today, most of which tend to only slow down the progression of the disease. It is our hope that Viro-Net will provide a better solution."
About PanaMed
PanaMed is in business to facilitate future testing and distribution of therapeutics for the treatment of serious health conditions such as HIV/AIDS. The therapeutics use "cellular signaling" techniques to teach the body's immune system how to fight off the invading virus. These products have not been submitted for FDA review and may not be offered for sale or use in the United States.
For more information on PanaMed, please contact TwoTrades.com at (888) 577-6898.
This document contains forward looking statements. There are certain important factors that could cause results to differ materially from those anticipated by the statements made above. Additional information on these and other factors will be included on future 10-Q and 10-K reports.
PanaMed Corporation
CONTACT: TwoTrades.com
Chip Parrish (Investor Relations), 888/577-6898
Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!
jmhollen
23 años hace
PanaMed Launches Operations as a Public Company
CAMARILLO, Calif.--(BW HealthWire)--March 5, 2002--PanaMed Inc. and Micron Solutions Inc. (OTCBB:MCSU - news) Tuesday announced they have completed a successful reorganization of management and the company has formally commenced operations as PanaMed Corp.
The ticker symbol will be changed to reflect the new company name within the next 10 days. ( PANA )
PanaMed has obtained exclusive licensing rights to distribute a proprietary line of immuno-modulating therapeutic compounds for the treatment of HIV/AIDS. Anecdotal human case study trials have shown the therapeutics to be effective in reversing the viral load to a non-detect level and maintaining the non-detect level over a five-year period of time.
In addition, the therapeutics are expected to provide a number of advantages over conventional AIDS medication, including: simple to administer (no shots), minimal side effects, effective against different HIV viral derivatives, cost effective, and non-patient specific. The therapeutics are particularly suitable for large scale patient treatment programs.
PanaMed plans to launch formal clinical trials, in April 2002, within the continent of Africa. Africa was chosen as the starting point for PanaMed's clinical trials and treatments due to its sizable base of AIDS patients which have not been exposed to conventional AIDS medication.
Although the therapeutics are expected to be effective when used in conjunction with or after conventional treatments, PanaMed prefers to work with patients which have not been previously so as to clearly show the effects of the therapeutics.
After successful completion of these trials, PanaMed plans to launch a massive distribution program to provide low-cost treatments to the tens of millions of people infected with this disease.
A press release issued earlier this year (http://www.who.int/inf/en/pr-2002-06.html) from the World Health Organization (WHO) and supporting organizations (UNICEF, UNAIDS, World Bank, UNESCO and UNFPA) announced a new report entitled ``Scaling Up the Response to Infectious Diseases: A Way Out of Poverty.''
The report calls for new investments in the treatment and prevention of TB, Malaria and HIV/AIDS through known interventions. ``Almost 6 million people are killed every year by HIV/AIDS, TB, and Malaria alone,'' said Carol Bellamy, UNICEF's executive director.
She goes on to say, ``Malaria and HIV are some of the major causes of stagnating, and in some cases, rising infant and under-five mortality in Africa. Tackling these, as well as addressing other important childhood disease will be essential to reaching the Millennium Development Goals for children.''
``We are very much encouraged by the recent announcements made by WHO and supporting organizations to provide future investments in the treatment of HIV/AIDS,'' stated Phil Butler, chief executive officer of PanaMed. ``In the past, WHO (and most AIDS-related foundations) have allocated sizable financial resources for AIDS prevention/education, without providing funding for treating the disease.
``With these funds becoming available, large-scale treatment programs can become a reality. It's PanaMed's objective to become a key contributor in resolving the HIV/AIDS health problems in Africa, which continue to destroy the economy and livelihood of the African people.''
About PanaMed
PanaMed was founded as a private company in August 2001 for the primary purpose of testing and distributing a proprietary line of therapeutics used for reversing HIV/AIDS. Quintek Technologies Inc. (OTCBB:QTEK - news) assisted in launching PanaMed and later acquired a 10 percent equity position in the company through a stock swap transaction.
In February 2002, PanaMed entered into a reorganization agreement with Micron Solutions Inc. to combine the assets, liabilities and operations of the two companies, with PanaMed management assuming control of the combined entity.
For more information on PanaMed, please contact TwoTrades.com at 888/577-6898.
Contact: PanaMed Chip Parrish, 888/577-6898
jmhollen
23 años hace
Micron and PanaMed Sign Reorganization Agreement
SCOTTSDALE, Ariz., Feb 28, 2002 (BUSINESS WIRE) -- Micron Solutions Inc.
(OTCBB: MCSU) Thursday announced that management has formally signed off on a
reorganization agreement to combine Micron with PanaMed Inc., a bio-tech company
based in Camarillo, Calif.
The reorganization will officially become effective as of March 1, 2002,
however, it will take several weeks to complete the numerous follow-up
transactions required. During this transition period the following changes will
be made:
-- The management of Micron will resign and the management of
PanaMed Inc. will assume control of the company
-- Micron will effect a 1:10 reverse split of its existing shares causing;
a) the amount of outstanding stock to change from 3,965,200
shares to 396,520 shares, and
b) the share price to increase to 10 times the trading price
quoted on the day of the split
-- The company name will be changed from Micron Solutions Inc.
to PanaMed Corp.
-- The ticker symbol will be changed to reflect the new company
name
-- New stock certificates will be prepared reflecting the reverse
split, a new CUSIP number and the new company name
-- The new stock certificates will be exchanged on a 1:1 basis
with the 396,520 shares of stock in Micron and approximately
21M shares of stock held by shareholders of PanaMed Inc.
-- The assets, liabilities, and operations of PanaMed Inc. and
Micron will be combined
About PanaMed
PanaMed has obtained exclusive rights to distribute a proprietary line of
therapeutics for the treatment of HIV/AIDS within third world countries.
Although the therapies have not been fully tested and evaluated in formal
trials, study trials have proven them to be very effective in reversing this
condition.
In addition, the therapies provide a number of benefits over conventional drug
therapies in that they are low in cost, simple to administer, have minimal side
effects, and are particularly suitable to support large scale patient treatment
programs. For more information on PanaMed, please contact TwoTrades.com at
888/577-6898.
CONTACT: PanaMed
Chip Parrish, 888/577-6898
Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Hot Features
Premium
